74 related articles for article (PubMed ID: 34257615)
1. Classification of Intrahepatic Cholangiocarcinoma into Perihilar Versus Peripheral Subtype.
Wei T; Lu J; Xiao XL; Weiss M; Popescu I; Marques HP; Aldrighetti L; Maithel SK; Pulitano C; Bauer TW; Shen F; Poultsides GA; Soubrane O; Martel G; Koerkamp BG; Itaru E; Lv Y; Zhang XF; Pawlik TM; ;
Ann Surg Oncol; 2024 Feb; 31(2):1232-1242. PubMed ID: 37930500
[TBL] [Abstract][Full Text] [Related]
2. CD73 expression in normal and pathological human hepatobiliopancreatic tissues.
Sciarra A; Monteiro I; Ménétrier-Caux C; Caux C; Gilbert B; Halkic N; La Rosa S; Romero P; Sempoux C; de Leval L
Cancer Immunol Immunother; 2019 Mar; 68(3):467-478. PubMed ID: 30607549
[TBL] [Abstract][Full Text] [Related]
3. Expression landscape of cancer-FOXP3 and its prognostic value in pancreatic adenocarcinoma.
Gong R; Wang J; Xing Y; Wang J; Chen X; Lei K; Yu Q; Zhao C; Li S; Zhang Y; Wang H; Ren H
Cancer Lett; 2024 May; 590():216838. PubMed ID: 38561039
[TBL] [Abstract][Full Text] [Related]
4. DECREASING ALBUMIN mRNA EXPRESSION IN CHOLANGIOCARCINOMAS ALONG THE BILE DUCT TREE.
Albertini E; Chillotti S; Monti G; Malvi D; Deserti M; Degiovanni A; Palloni A; Tavolari S; Brandi G; D'Errico A; Vasuri F
Pathobiology; 2024 May; ():. PubMed ID: 38763129
[TBL] [Abstract][Full Text] [Related]
5. Liver metastases of colorectal adenocarcinoma with intrahepatic biliary spread pattern: clinical manifestation and importance of immunohistochemical analysis.
Díaz Vico T; Castellón Pavón CJ; Díaz García GA; Torres Alemán A; Pérez Domene MT; Sánchez Infante S; Fuel Gómez DC; Durán Poveda M
Clin J Gastroenterol; 2023 Oct; 16(5):693-697. PubMed ID: 37306864
[TBL] [Abstract][Full Text] [Related]
6. Combined analysis of albumin in situ hybridisation and C reactive protein immunohistochemistry for the diagnosis of intrahepatic cholangiocarcinoma: towards a molecular classification paradigm.
Albrecht T; Rossberg A; Rose F; Breuhahn K; Baumann EM; Tóth M; Brinkmann F; Charbel A; Vogel MN; Köhler B; Mehrabi A; Büchler MW; Singer S; Solass W; Straub B; Schirmacher P; Roessler S; Goeppert B
J Clin Pathol; 2024 May; ():. PubMed ID: 38749660
[TBL] [Abstract][Full Text] [Related]
7. Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity.
Cardinale V; Carpino G; Reid L; Gaudio E; Alvaro D
World J Gastrointest Oncol; 2012 May; 4(5):94-102. PubMed ID: 22645632
[TBL] [Abstract][Full Text] [Related]
8. Establishment and characterization of a novel hilar cholangiocarcinoma cell line, CBC3T-1.
Bai M; Jiang N; Fu W; Huang C; Tian L; Mi N; Gao L; Ma H; Lu Y; Cao J; Zhang C; Yue P; Zhang Y; Lin Y; Meng W; Li X
Hum Cell; 2024 Jan; 37(1):364-375. PubMed ID: 37966669
[TBL] [Abstract][Full Text] [Related]
9. Demographics, tumor characteristics, treatment, and survival of patients with Klatskin tumors.
Sharma P; Yadav S
Ann Gastroenterol; 2018; 31(2):231-236. PubMed ID: 29507471
[TBL] [Abstract][Full Text] [Related]
10. Forkhead box F1 functions as a novel prognostic biomarker and induces caspase‑dependent apoptosis in bladder cancer.
Hao Y; He W; Wang H; Rui W; Sun F; Zhu Y; Xu D; Wang C
Oncol Rep; 2023 Sep; 50(3):. PubMed ID: 37539708
[TBL] [Abstract][Full Text] [Related]
11. MALDI Mass Spectrometry Imaging for the Distinction of Adenocarcinomas of the Pancreas and Biliary Tree.
Bollwein C; Gonҫalves JPL; Utpatel K; Weichert W; Schwamborn K
Molecules; 2022 May; 27(11):. PubMed ID: 35684402
[TBL] [Abstract][Full Text] [Related]
12. Hilar cholangiocarcinoma is pathologically similar to pancreatic duct adenocarcinoma: suggestions of similar background and development.
Nakanuma Y; Sato Y
J Hepatobiliary Pancreat Sci; 2014 Jul; 21(7):441-7. PubMed ID: 24446421
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical Markers Distinguishing Cholangiocellular Carcinoma (CCC) from Pancreatic Ductal Adenocarcinoma (PDAC) Discovered by Proteomic Analysis of Microdissected Cells.
Padden J; Ahrens M; Kälsch J; Bertram S; Megger DA; Bracht T; Eisenacher M; Kocabayoglu P; Meyer HE; Sipos B; Baba HA; Sitek B
Mol Cell Proteomics; 2016 Mar; 15(3):1072-82. PubMed ID: 26644413
[TBL] [Abstract][Full Text] [Related]
14. Multidisciplinary treatment for hilar and intrahepatic cholangiocarcinoma: A review of the general principles.
Sapisochin G; Ivanics T; Subramanian V; Doyle M; Heimbach JK; Hong JC
Int J Surg; 2020 Oct; 82S():77-81. PubMed ID: 32380231
[TBL] [Abstract][Full Text] [Related]
15. Pathology of cholangiocellular carcinoma.
Hrudka J; Oliverius M; Gürlich R
Cas Lek Cesk; 2019; 158(2):57-63. PubMed ID: 31109164
[TBL] [Abstract][Full Text] [Related]
16. FOXF1 as an Immunohistochemical Marker of Hilar Cholangiocarcinoma or Metastatic Pancreatic Ductal Adenocarcinoma. Single Institution Experience.
Hrudka J; Prouzová Z; Mydlíková K; Jedličková K; Holešta M; Whitley A; Havlůj L
Pathol Oncol Res; 2021; 27():1609756. PubMed ID: 34257615
[TBL] [Abstract][Full Text] [Related]
17. Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules.
Gandou C; Harada K; Sato Y; Igarashi S; Sasaki M; Ikeda H; Nakanuma Y
Hum Pathol; 2013 May; 44(5):811-21. PubMed ID: 23134772
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
